1‐Year Clinical Outcome Post‐Myasthenic Crisis: A Multicenter Prospective Study in China
European Journal of Neurology · 2026-02 · 33 (2)
DOI: 10.1111/ene.70513 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift European Journal of Neurology, online erschienen am 27.01.2026. Verfasst von Xiao Huan und 27 weiteren Autor:innen. Beteiligte Einrichtung: Huashan Rare Disease Center and Department of Neurology, Huashan Hospital, Shanghai Medical College, National Center for Neurological Disorders, Fuda…. Hauptthemen laut MEDLINE: Myasthenia Gravis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Shanghai Municipal Hospital Development Center.
Abstract (Originalsprache)
Background
Myasthenic crisis (MC) affects 10%–20% of myasthenia gravis patients and is life‐threatening with significant economic burden, yet its long‐term outcomes remain poorly understood. This prospective multicentre study aimed to evaluate 1‐year clinical outcomes after MC.
Methods
This study enrolled patients with MC between December 2018 and October 2024 and prospectively followed at 1, 2, 3, 6, and 12 months post‐MC. Outcome measures included Myasthenia Gravis Foundation of America (MGFA) postintervention status (PIS) classification at 1 year after MC, all‐cause mortality, and complications.
Results
The cohort comprised 277 patients with 282 MC episodes with a follow‐up duration of 29.16 ± 15.93 months. The in‐hospital mortality was 5.05% (14/277), while the all‐cause mortality was 15.16% (42/277). The leading causes of death were septic shock (35.7%) and multiple organ failure (21.4%). Among 247 patients with complete 1‐year follow‐up, 79.76% (197/247) achieved favorable outcomes. MG‐ADL scores reduced from 21.3 ± 2.1 at baseline to 5.5 ± 1.5 at 6 months, and 2.8 ± 1.1 at 1 year post‐MC ( p < 0.01). Multivariable analysis identified older age at crisis (OR 1.03, p = 0.003), thymoma comorbidity (OR 1.84, p = 0.041), higher comorbidity burden (Charlson Comorbidity Index ≥ 3, OR 2.68, p = 0.003), and prolonged ICU stay (OR 1.03, p = 0.002) as independent predictors for minimal symptom expression non‐responders. The most frequent chronic complications included infections (15.2%; predominantly fungal pathogens), gastrointestinal disorders (8.3%), and osteoporosis/fractures (5.1%).
Conclusions
This is the first prospective cohort study to report clinical outcomes in MG patients at post‐MC stage, highlighting the importance of disease monitoring and early intervention to improve patient‐centred care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Huashan Rare Disease Center and Department of Neurology, Huashan Hospital, Shanghai Medical College, National Center for Neurological Disorders, Fudan University, Shanghai, China.
- Department of Blood Transfusion, Huashan Hospital, Fudan University, Shanghai, China.
- Department of Neurosurgery & Neurocritical Care, Huashan Hospital, Fudan University, Shanghai, China.
- Department of Infectious Diseases, Huashan Hospital, National Medical Center for Infectious Diseases, Fudan University, Shanghai, China.
- Department of Neurology, Wuhan no. 1 Hospital, Wuhan, China.
- Department of Neurology, the First People's Hospital of Changzhou, Third Affiliated Hospital of, Soochow University, Changzhou, China.
ORCID-Profile: Yafang Xu, Jianming Zheng, Zhe Ruan, Wanlong Wu, Huahua Zhong, Chongbo Zhao, Sushan Luo
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Shanghai Municipal Hospital Development Center
Zitieren
APA
Huan, X., Chen, R., Jin, L., Wang, Y., Xu, Y., Yang, L., Xi, C., Zheng, J., Luo, L., Yang, S., Shi, J., Liu, Y., Ruan, Z., Wu, W., Li, W., Yue, Y., Li, Y., Jia, W., Zhong, H., …, & Chinese Myasthenia Gravis Collaborating Group (CMGCG) (2026). 1‐Year Clinical Outcome Post‐Myasthenic Crisis: A Multicenter Prospective Study in China. European Journal of Neurology, 33(2). https://doi.org/10.1111/ene.70513
Vancouver
Huan X, Chen R, Jin L, Wang Y, Xu Y, Yang L, et al. 1‐Year Clinical Outcome Post‐Myasthenic Crisis: A Multicenter Prospective Study in China. European Journal of Neurology. 2026;33(2). doi:10.1111/ene.70513
BibTeX
@article{Huan2026,
author = {Huan, Xiao and Chen, Ran and Jin, Lei and Wang, Yuan and Xu, Yafang and Yang, Lei and Xi, Caihua and Zheng, Jianming and Luo, Lijun and Yang, Song and Shi, Jianquan and Liu, Yanping and Ruan, Zhe and Wu, Wanlong and Li, Wei and Yue, Yaoxian and Li, Yarong and Jia, Wenji and Zhong, Huahua and Yan, Chong and Song, Jie and Xi, Jianying and Tan, Song and Jiang, Qilong and Zou, Zhangyu and Zhao, Chongbo and Luo, Sushan and Chinese Myasthenia Gravis Collaborating Group (CMGCG), Chinese Myasthenia Gravis Collaborating Group (CMGCG)},
title = {1‐Year Clinical Outcome Post‐Myasthenic Crisis: A Multicenter Prospective Study in China},
journal = {European Journal of Neurology},
year = {2026},
volume = {33},
number = {2},
doi = {10.1111/ene.70513}
}
EUVIMED